- Home
- BCAX vs IMTX Comparison
BCAX vs IMTX Comparison
Compare BCAX & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAX
- IMTX
- Stock Information
- Founded
- BCAX 2018
- IMTX N/A
- Country
- BCAX United States
- IMTX Germany
- Employees
- BCAX N/A
- IMTX N/A
- Industry
- BCAX
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCAX
- IMTX Health Care
- Exchange
- BCAX NYSE
- IMTX Nasdaq
- Market Cap
- BCAX 670.9M
- IMTX 579.8M
- IPO Year
- BCAX 2024
- IMTX N/A
- Fundamental
- Price
- BCAX $12.97
- IMTX $4.24
- Analyst Decision
- BCAX Buy
- IMTX Strong Buy
- Analyst Count
- BCAX 7
- IMTX 4
- Target Price
- BCAX $29.67
- IMTX $16.67
- AVG Volume (30 Days)
- BCAX 586.0K
- IMTX 403.1K
- Earning Date
- BCAX 05-20-2025
- IMTX 05-20-2025
- Dividend Yield
- BCAX N/A
- IMTX N/A
- EPS Growth
- BCAX N/A
- IMTX N/A
- EPS
- BCAX N/A
- IMTX 0.14
- Revenue
- BCAX N/A
- IMTX $161,336,577.00
- Revenue This Year
- BCAX N/A
- IMTX N/A
- Revenue Next Year
- BCAX N/A
- IMTX $4.92
- P/E Ratio
- BCAX N/A
- IMTX $29.87
- Revenue Growth
- BCAX N/A
- IMTX 188.60
- 52 Week Low
- BCAX $8.91
- IMTX $3.30
- 52 Week High
- BCAX $28.09
- IMTX $13.77
- Technical
- Relative Strength Index (RSI)
- BCAX N/A
- IMTX 43.11
- Support Level
- BCAX N/A
- IMTX $3.94
- Resistance Level
- BCAX N/A
- IMTX $5.41
- Average True Range (ATR)
- BCAX 0.00
- IMTX 0.35
- MACD
- BCAX 0.00
- IMTX -0.04
- Stochastic Oscillator
- BCAX 0.00
- IMTX 20.41
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.